Abstract
To assess the impacts of application site (buttock, abdomen, or upper torso [excluding breast]) and body mass index (BMI) on adhesion and local tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system (TDS; 120 μg/day levonorgestrel, 30 μg/day ethinyl estradiol). The TDS is indicated as a method of contraception for use in women of reproductive potential with a BMI <30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
